Treatment.com AI Stock Price, News & Analysis

Treatment.com AI (TREIF) has launched an updated Medical Education Suite (MES), an AI-powered clinical skills assessment platform, successfully deployed at the University of Minnesota Medical School. The platform, which incorporates AI-simulated patients and real-time scoring, was tested with 240 third-year medical students and demonstrated potential cost savings of approximately 40%. The MES leverages the Global Library of Medicine (GLM), a clinician-built medical knowledge engine, to provide objective evaluations, reduce faculty workload, and enhance clinical skills training. Key features include real-time scoring aligned with learning objectives, secure exam delivery options, and integration with existing OSCE workflows. The University of Minnesota implementation showed complete technical reliability, and Treatment.com AI plans to expand the platform across North America, the UK, and other international markets.

Treatment.com AI's subsidiary Rocket Doctor has been selected for the 2025 Heal.LA Bioscience and Healthcare Accelerator Cohort. As one of 15 companies chosen, Rocket Doctor will receive strategic mentorship, regulatory guidance, and access to Larta's Ecosystem Action Network to expand its virtual healthcare platform in underserved communities. The company's physician-led platform uses AI-enabled tools and connected diagnostic devices to deliver remote care. CEO Dr. William Cherniak expects the program to drive patient bookings and growth in Los Angeles and Southern California. The selection validates Rocket Doctor's innovative approach to making healthcare more accessible through technology.

Treatment.com AI (CSE: TRUE, OTC: TREIF) and its virtual care platform, Rocket Doctor, have received recognition from three prestigious healthcare innovation organizations. The company was selected for UC Berkeley's Health Engine non-dilutive accelerator program for high-impact healthcare startups. At Harvard University, CEO Dr. William Cherniak was invited to speak about Rocket Doctor's transformation of healthcare delivery through virtual care, AI, and connected devices. Additionally, at the AARP AgeTech Conference, Dr. Cherniak presented the company's approach to improving care for Medicaid and Medicare patients.

These recognitions follow Rocket Doctor's recent award as Clinical Innovator of the Year at the American Telemedicine Association's NEXUS 2025 Innovators Challenge. The company focuses on using technology to reduce barriers to care and streamline access for underserved populations.

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) announced that its virtual care subsidiary, Rocket Doctor, has partnered with Melanoma Canada to provide follow-up care for patients identified as at-risk during mobile skin cancer screenings. The partnership will facilitate direct referrals to Rocket Doctor physicians through a digital intake process for patients without family doctors across Ontario, Alberta, and British Columbia.

The collaboration involves Melanoma Canada's Mole Mobile units, which offer free skin cancer screenings in remote and urban communities. The initiative addresses a critical healthcare need, as skin cancer represents 1 in 3 cancer diagnoses in Canada, with 22 Canadians diagnosed with melanoma daily. The 12-month agreement, starting February 3, 2025, includes branding opportunities on Mole Mobile vans and campaign materials.

Treatment.com AI (TREIF) and its subsidiary Rocket Doctor received validation from US Health Secretary RFK Jr.'s recent advocacy for increased telehealth and AI investment. During a House Appropriations Committee Budget Hearing, Kennedy emphasized the potential of telehealth and AI to reduce ER visits through at-home treatment. Rocket Doctor currently operates in New York and California, serving Medicare and Medicaid patients with AI-powered remote diagnostic capabilities. The platform has helped over 4,000 patients avoid emergency care and was named Clinical Innovator of the Year by the American Telemedicine Association. Treatment.com's Global Library of Medicine (GLM), an AI engine developed with input from hundreds of healthcare professionals, enhances the platform by supporting diagnosis and care planning through various interfaces including health chatbots and voice agents.

Treatment.com AI's subsidiary Rocket Doctor has been awarded Clinical Innovator of the Year at NEXUS 2025's Innovators Challenge in New Orleans. The company's platform enables independent physicians to manage virtual or hybrid practices with built-in support and AI tools. CEO Dr. William Cherniak is presenting at multiple high-profile events including Harvard University, AARP's AgeTech Founder's Day, and UC Berkeley's Health Engine Accelerator Demo Day. Rocket Doctor's technology supports various care types, from urgent visits to complex consults, allowing physicians to provide care virtually without traditional clinics. The platform operates across Canada and the United States, focusing on expanding healthcare access to underserved communities.

Treatment.com AI (TREIF) has signed a Collaborative Agreement with Beijing Aiyi Botong Information Technology (Aiyibotong) to explore commercial opportunities for Clinical Decision Support Systems (CDSS) in China and Far East markets. The partnership aims to combine Treatment's Global Library of Medicine (GLM) with Aiyibotong's CDSS technology.

Key highlights:

• China's CDSS market expected to reach ~US$600 million by 2030
• Aiyibotong has installations in over 200 healthcare institutions in China
• Digital Health investment in China projected to hit US$45 billion in 2025

The collaboration focuses on:

• GLM content localization and alignment with Chinese medical consensus
• Technology licensing and CDSS platform integration
• Co-marketing initiatives in China
• Development of AI-based CDSS for the global market

Treatment.com AI (TREIF) has signed a Collaborative Agreement with Beijing Aiyi Botong Information Technology (Aiyibotong) to explore commercial opportunities for Clinical Decision Support Systems (CDSS) in China and Far East markets. The partnership aims to combine Treatment's Global Library of Medicine (GLM) with Aiyibotong's CDSS technology.

Key highlights:

• China's CDSS market expected to reach ~US$600 million by 2030
• Aiyibotong has installations in over 200 healthcare institutions in China
• Digital Health investment in China projected to hit US$45 billion in 2025

The collaboration includes GLM content localization, technology licensing, co-marketing initiatives, and joint development of AI-based CDSS for the global market. The agreement was signed on February 19, 2025, with no associated costs.

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) announces significant growth of Rocket Doctor's virtual healthcare platform in Alberta. The platform has served over 71,000 Albertans, with 35% from communities under 25,000 population.

Key achievements include:

• 112% increase in patient visits year-over-year, serving 36,779 patients
• 218% growth in new physicians joining the platform, with 48 new doctors onboard
• 4.4-star Google rating from over 2,400 reviews

Rocket Doctor's model enables independent physicians to operate efficiently while covered under Alberta's provincial health insurance. The company plans to integrate AI-driven tools and expand its services across Canada. Treatment.com AI Inc. has a definitive share purchase agreement dated February 11, 2025, to acquire Rocket Doctor Inc.